Bruker Corporation (Nasdaq: BRKR), a provider of high performance scientific instruments and high value analytical and diagnostic solutions, announced on Monday that it has launched the Dimension Nexus atomic force microscope (AFM), marking a new standard in cost-effective, large-sample AFM systems.
Revealed on 19 December 2023 at the 2024 MRS Fall Meeting, Dimension Nexus expands the company's renowned Dimension product line, which boasts over 4,600 global installations. Equipped with the advanced NanoScope 6 controller, it offers seamless access to Bruker's proprietary PeakForce Tapping technology and over 50 specialised AFM modes, targeting growing laboratories and multi-user facilities.
Designed with low noise, low drift and open architecture, Dimension Nexus combines high performance with affordability. Its NanoScope 6 controller enhances productivity, while exclusive features like ScanAsyst simplify operations. The system supports advanced modes including AFM-nDMA for viscoelastic analysis and PeakForce QNM for mechanical property mapping. A programmable stage further enables high-throughput, multi-site analysis, making it a versatile solution for cutting-edge research.
Bruker Corporation continues to innovate in post-genomic scientific instrumentation, supporting breakthroughs in life sciences, nanoanalysis and advanced semiconductor research.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA